Pharm
Dinoprostone
search
Dinoprostone
, PGE2 Gel, Cervidil, Prepidil, Prostin E2
See Also
Cervical Ripening Agents
Cervical Ripening
Labor Induction
Misoprostol
Prostaglandin
Indications
Cervical Ripening
in
Labor Induction
Bishop Score
<6
Membranes intact
No active contraction pattern
Less than 10 mild contractions per hour
Evacuation of Uterine Contents after Fetal Death
Up to 28 weeks gestation
Contraindications
Uterine Contractions >3 in 10 minutes prior to placement
Factors increasing the risk for
Uterine Rupture
Prior
Cesarean Section
Major uterine surgery with scar dehiscence risk
Mechanism
See
Prostaglandin
Dinoprostone is a synthetic
Prostaglandin
E2 (PGE2) analog
Prostaglandin
E2 (PGE2) is the most common and the most biologically active
Prostaglandin
Dinoprostone induces smooth
Muscle Contraction
in the
Uterus
(myometrium) and
Stomach
Increases cAMP levels, activating adenylate cyclase, and increasing
Calcium Ion
transport across cell membranes
Precautions
Monitor
Fetal Heart Rate
and tocometry in
Cervical Ripening
Start 15 to 30 minutes before
Vaginal Gel monitoring should continue for 30-120 minutes after gel placement
Vaginal Insert monitoring should continue while inserted, and for 15 min after removal
Medications
Cervical Ripening Agents
for
Labor Induction
Dinoprostone Gel (PGE2 Gel, Prepidil): 0.5 mg per 3 g syringe
Dinoprostone
Pessary
or Vaginal Insert (PGE2, Cervidil): 10 mg
Evacuation of Uterine Contents after Fetal Death or
Termination of Pregnancy
Dinoprostone Vaginal Suppository (Prostin E2): 20 mg
Dosing
Dinoprostone Gel (PGE2 Gel, Prepidil) for
Cervical Ripening
Initiate
Fetal Heart Rate
and tocometry
Start 15-30 minutes before gel inserted
Continue monitoring for 30-120 minutes after placement
Insertion Technique
Use one syringe of gel (0.5 mg in 3cc KY)
Patient remains supine for 30 minutes after insertion
Introduce gel into
Cervix
Cervix
not effaced: Use 20 mm catheter
Cervix
effaced 50% or greater: Use 10 mm catheter
Intracervical is preferred over posterior fornix
Perry (2004) Obstet Gynecol 103:13-7 [PubMed]
Dosing
May repeat every 6 hours up to 3 doses in 24 hours
End points
Bishop Score
of 8 or greater
Strong uterine contractions
Drug Interaction
s
Wait 6-12 hours before starting
Oxytocin
Dosing
Dinoprostone
Pessary
or Vaginal Insert (PGE2, Cervidil) for
Cervical Ripening
Dinoprostone 10 mg vaginal insert releases Dinoprostone at 0.3 mg/hour for 12 hours
Insert
Pessary
into posterior fornix (adjacent to
Cervix
)
Monitor
Fetal Heart Tones
and tocometry
Start 15 to 30 minutes before insertion
Continue monitoring for 15 minutes after removal
Patient remains recumbent for 2 hours after insertion
Pull
Pessary
out via string if hyper-stimulated
Dosing
Dinoprostone Vaginal Suppository (Prostin E2) in Evacuation of Uterine Contents
Indicated in up to 28 weeks gestation for Fetal in utero death
Insert 20 mg intravaginal suppository
May repeat up to every 3 to 5 hours (maximum use 2 days) as needed until uterine contents expelled
Adverse Effects
Uterine Tachysystole
Criteria: >10 contractions in 20 minutes (or >5 contractions in 10 minutes)
Dinoprostone Tachysystole
Incidence
: 33%
Uterine Hyperstimulation
Criteria
Exaggerated uterine response (i.e. Tachysystole)
Concerning
Fetal Heart Rate
tracing
Late Deceleration
s
Fetal Tachycardia
>160 beats per minute
Dinoprostone Hyperstimulation
Incidence
: 17%
Hyperstimulation Management
Remove Dinoprostone
Consider
Terbutaline
SQ
Uterine Rupture
in
VBAC
Risk: 2.5% in
Trial of Labor after Cesarean
References
Crane (2001) Obstet Gynecol 97:926-31 [PubMed]
Ravasia (2000) Obstet Gynecol 183:1176-9 [PubMed]
Safety
Unknown safety in
Lactation
Pregnancy use only in peripartum (or intended evacuation of
Uterus
)
Resources
Dinoprostone Vaginal Insert (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3bc9031-0620-4a50-b440-f661cadfeb1d
Dinoprostone Gel (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab03de5b-782c-4f81-a8dc-7ef9969dd0cf
References
Adair (2000) Clin Obstet Gynecol 43:447-54 [PubMed]
Crane (2001) Obstet Gynecol 97:926-31 [PubMed]
Sanchez-Ramos (1997) Obstet Gynecol 89:633-4 [PubMed]
Tenore (2003) Am Fam Physician 67(10):2123-8 [PubMed]
Wheeler (2022) Am Fam Physician 105(2): 177-86 [PubMed]
Type your search phrase here